CD19 chimeric antigen receptor (CAR) T-cell therapy emerged as a novel treatment in autoimmune diseases. Refractory autoimmune hemolytic anemia (rAIHA) is characterized by life-threatening hemolysis, and traditional B-cell-targeting treatments often fail to halt the disease. We hypothesize that resetting aberrant autoimmunity through deep depletion of B cells by CD19 CAR T-cell could be a potential strategy for rAIHA to achieve sustained drug-free remission (DFR).
Refractory AIHA patients who had failed at least three lines of therapies were enrolled in a compassionate-use CD19 CAR T-cell program (n = 5) and phase I clinical trial (NCT06231368) (n = 3) to evaluate the safety and efficacy. Patients received a single dose infusion of autologous CD19 CAR T-cell 1×106 cells/kg (compassionate use) and 0.5×106 cells/kg (phase I clinical trial, dose 1) respectively after preconditioning with fludarabine (25 mg/m²/day on days -5 to -3) and cyclophosphamide (1.0 g/m²/day on day -3). Safety assessments included cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), hematologic and non-hematologic toxicities were assessed according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Efficacy was evaluated based on hemoglobin levels and biochemical markers of hemolysis. Single-cell RNA sequencing (scRNA-seq) and single-cell V(D)J sequencing were performed to monitor the process of B cell reconstitution in bone marrow (BM) and peripheral blood (PB) at baseline, 12 weeks (W12), and month 6 (M6) after CD19 CAR T-cell infusion.
As of July 31, 2024, the median follow-up time for the 8 patients were 6.8 months (range, 0.8-10.5 months). The safety profile in these 8 patients was satisfactory: 5 patients experienced grade 1 CRS, and two patients experienced grade 2 CRS. One patient each had grade 1 CRS and grade 1 ICANS. No hospitalization due to severe infections occurred during the follow-up period. Among the 7 patients currently evaluable for efficacy, all achieved complete remission (CR), yielding a CR rate of 100%. One relapse was observed in compassionate-use UPN2 of at 6.8 months, maintaining DFR for 6.3 months. The median duration of sustained DFR was 6.3 months (range, 1.3-9.7 months). The median time to partial remission (PR) was 15 days (range, 11-27 days) and to CR was 57 days (range, 26-118 days). CAR T-cell levels rapidly expanded after infusion, reaching peak concentrations at a median time of 10 days (range, 7-11 days). At the peak of expansion, the median number of circulating CAR T-cell was 118.8 cells/ul (range, 44.9 to 244.6 cells/ul). B-cell aplasia lasted a median of 85 days (range, 57-91 days) in 6 patients who have undergone immune B cells reconstitution. scRNA-seq and single-cell V(D)J sequencing data showed that B-cell lineage and plasmablasts were reset in both BM and PB.
CD19 CAR T-cell therapy induce rapid remission, unprecedented DFR, and favorable safety profile in rAIHA patients. These exciting data support CAR T-cell as a novel strategy for autoimmune hemolytic anemia, and provide rationale for further clinical trials.
No relevant conflicts of interest to declare.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal